Bartter and Gitelman syndromes
Authors:
Jakub Zieg 1; Zdeněk Doležel 2
Authors place of work:
Pediatrická klinika 2. LF UK a FN Motol, Praha
1; Pediatrická klinika LF MU a FN Brno
2
Published in the journal:
Čas. Lék. čes. 2022; 161: 131-134
Category:
Review Article
Summary
Bartter and Gitelman syndromes belong to salt-losing tubulopathies. These rare diseases may be associated with severe electrolyte disorders. Early identification of tubulopathies is essential for appropriate management. Progress in molecular genetics enabled the identification of genes and pathophysiologic mechanisms associated with these diseases. Here, we review etiology and diagnostics of these disorders from the light of current knowledge. Additionally, we discuss contemporary therapeutic approaches.
Keywords:
management – tubulopathy – Bartter syndrome – Gitelman syndrome
Zdroje
1. Bartter FC, Pronove P, Gill JR jr. et al. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 1962; 33: 811–828.
2. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 1966; 79: 221–235.
3. Walsh PR, Tse Y, Ashton E et al. Clinical and diagnostic features of Bartter and Gitelman syndromes. Clin Kidney J 2018; 11: 302–309.
4. Reinalter SC, Jeck N, Brochhausen C et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002; 62: 253–260.
5. Konrad M, Nijenhuis T, Ariceta G et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int 2021; 99: 324–335.
6. Besouw MTP, Kleta R, Bockenhauer D. Bartter and Gitelman syndromes: Questions of class. Pediatr Nephrol 2020; 35: 1815–1824.
7. Laghmani K, Beck BB, Yang SS et al. Polyhydramnios, transient antenatal Bartter's syndrome, and MAGED2 mutations. N Engl J Med 2016; 374: 1853–1863.
8. Zieg J, Gonsorčíková L, Landau D. Current views on the diagnosis and management of hypokalaemia in children. Acta Paediatr 2016; 105: 762–772.
9. Finer G, Shalev H, Birk OS et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr 2003; 142: 318–323.
10. Yang X, Zhang G, Wang M et al. Bartter syndrome type 3: Phenotype-genotype correlation and favorable response to ibuprofen. Front Pediatr 2018; 6: 153.
11. Doležel Z, Cheong HI, Holeszová A et al. Bartterův syndrom – klinicko-genetická analýza. Pediatrie pro praxi 2015; 16: 179–182.
12. Knoers NV, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis 2008; 3: 22.
13. Doležel Z, Papež J, Jeřábek M. Gitelmanův syndrom. Pediatrie pro praxi 2021; 22: 216–217.
14. Tammaro F, Bettinelli A, Cattarelli D et al. Early appearance of hypokalemia in Gitelman syndrome. Pediatr Nephrol 2010; 25: 2179–2182.
15. Blanchard A, Bockenhauer D, Bolignano D et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2017; 91: 24–33.
16. Di Meglio L, Castaldo G, Mosca C et al. Congenital chloride diarrhea clinical features and management: a systematic review. Pediatr Res 2021; 90: 23-29.
17. Jdiaa SS, Walsh SB, Bockenhauer D et al. The hypokalemia mystery: distinguishing Gitelman and Bartter syndromes from 'pseudo-Bartter syndrome'. Nephrol Dial Transplant 2020; 37: 29–30.
18. Adalat S, Hayes WN, Bryant WA et al. HNF1B mutations are associated with a Gitelman-like tubulopathy that develops during childhood. Kidney Int Rep 2019; 4: 1304–1311.
19. Bockenhauer D, Feather S, Stanescu HC et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009; 360: 1960–1970.
20. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 2001; 8: 345–357.
21. Buyukcelik M, Keskin M, Kilic BD et al. Bartter syndrome and growth hormone deficiency: three cases. Pediatr Nephrol 2012; 27: 2145–2148.
22. Reinalter SC, Grone HJ, Konrad M et al. Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 2001; 139: 398–406.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
2022 Číslo 3-4
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Bartter and Gitelman syndromes
- Současná bariatrická/metabolická chirurgie
- Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection – a ten-year single-center experience
- Use of unmanned aerial systems in the health care